問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Infectious Disease

Division of Urology

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

蕭世欣Hsiao, Shih-Hsin
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

篩選

List

32Cases

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).
  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2021-09-01 - 2023-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2025-08-01 - 2031-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-05-01 - 2026-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-05-01 - 2028-06-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-07-11 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-07-07 - 2026-07-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2014-09-30 - 2020-02-21

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-10-01 - 2015-09-30

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2 3 4